TB500 TFA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 465354

CAS#: TB500 Acetate

Description: TB-500 is a synthetic version of an active region of thymosin β4. TB 500 promotes endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and decrease inflammation. A veterinary preparation known as TB-500 and containing a synthetic version of the naturally occurring peptide LKKTETQ has emerged. The peptide segment (17)LKKTETQ(23) is the active site within the protein thymosin β(4) responsible for actin binding, cell migration and wound healing. The key ingredient of TB-500 is the peptide LKKTETQ with artificial acetylation of the N-terminus. TB-500 is claimed to promote endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and decrease inflammation.

Chemical Structure

img
TB500 TFA
CAS# TB500 Acetate
Instruction

Theoretical Analysis

MedKoo Cat#: 465354
Name: TB500 TFA
CAS#: TB500 Acetate
Chemical Formula: C40H68F3N9O17
Exact Mass: 889.48
Molecular Weight: 1,004.025
Elemental Analysis: C, 47.85; H, 6.83; F, 5.68; N, 12.56; O, 27.09

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 885340-08-9   TB500 TFA   75591-33-4,  

Synonym: TB500 TFA; TB500 trifluoroacetate salt; TB500; TB 500; TB-500; thymosin β4 acetate; AcLKKTETE;

IUPAC/Chemical Name: acetyl-L-leucyl-L-lysyl-L-lysyl-L-threonyl-L-glutamyl-L-threonyl-L-glutamic acid, tritfluoroacetic acid

InChi Key: FWYSAPIGICJMKO-PFWNPZQHSA-N

InChi Code: InChI=1S/C38H67N9O15.C2HF3O2/c1-19(2)18-27(41-22(5)50)35(58)43-23(10-6-8-16-39)32(55)42-24(11-7-9-17-40)33(56)46-30(20(3)48)36(59)44-25(12-14-28(51)52)34(57)47-31(21(4)49)37(60)45-26(38(61)62)13-15-29(53)54;3-2(4,5)1(6)7/h19-21,23-27,30-31,48-49H,6-18,39-40H2,1-5H3,(H,41,50)(H,42,55)(H,43,58)(H,44,59)(H,45,60)(H,46,56)(H,47,57)(H,51,52)(H,53,54)(H,61,62);(H,6,7)/t20-,21-,23+,24+,25+,26+,27+,30+,31+;/m1./s1

SMILES Code: O=C(O)CC[C@@H](C(O)=O)NC([C@H]([C@H](O)C)NC([C@H](CCC(O)=O)NC([C@H]([C@H](O)C)NC([C@H](CCCCN)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC(C)=O)=O)=O)=O)=O)=O)=O.O=C(O)C(F)(F)F

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,004.03 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Judák P, Van Eenoo P, Deventer K. Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5. Anal Biochem. 2017 Nov 15;537:69-71. doi: 10.1016/j.ab.2017.09.003. Epub 2017 Sep 5. PMID: 28887173.

2: Zvereva I, Semenistaya E, Krotov G, Rodchenkov G. Comparison of various in vitro model systems of the metabolism of synthetic doping peptides: Proteolytic enzymes, human blood serum, liver and kidney microsomes and liver S9 fraction. J Proteomics. 2016 Oct 21;149:85-97. doi: 10.1016/j.jprot.2016.08.016. Epub 2016 Aug 26. PMID: 27569051.

3: Thomas A, Görgens C, Guddat S, Thieme D, Dellanna F, Schänzer W, Thevis M. Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry. J Sep Sci. 2016 Jan;39(2):333-41. doi: 10.1002/jssc.201501060. Epub 2015 Dec 15. PMID: 26578461.

4: Semenistaya E, Zvereva I, Krotov G, Rodchenkov G. Solid-phase extraction of small biologically active peptides on cartridges and microelution 96-well plates from human urine. Drug Test Anal. 2016 Sep;8(9):940-9. doi: 10.1002/dta.1890. Epub 2015 Oct 16. PMID: 26472487.

5: Esposito S, Deventer K, Geldof L, Van Eenoo P. In vitro models for metabolic studies of small peptide hormones in sport drug testing. J Pept Sci. 2015 Jan;21(1):1-9. doi: 10.1002/psc.2710. Epub 2014 Dec 3. PMID: 25469748.

6: Thevis M, Thomas A, Schänzer W. Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Rev Proteomics. 2014 Dec;11(6):663-73. doi: 10.1586/14789450.2014.965159. Epub 2014 Nov 8. PMID: 25382550.

7: Thevis M, Schänzer W. Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls. J Pharm Biomed Anal. 2014 Dec;101:66-83. doi: 10.1016/j.jpba.2014.05.020. Epub 2014 May 23. PMID: 24906629.

8: Kwok WH, Ho EN, Lau MY, Leung GN, Wong AS, Wan TS. Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry. Anal Bioanal Chem. 2013 Mar;405(8):2595-606. doi: 10.1007/s00216-012-6697-9. Epub 2013 Jan 15. PMID: 23318763.

9: Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK, Schiff PJ, Stewart BD. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012 Nov 23;1265:57-69. doi: 10.1016/j.chroma.2012.09.043. Epub 2012 Sep 23. PMID: 23084823.

10: Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012 Sep;4(9):733-8. doi: 10.1002/dta.1402. Epub 2012 Sep 7. PMID: 22962027.